Home | Business News | Browse by Publication | P | Pharma Marketletter

Teva and Lundbeck set to file rasagiline for Parkinson''s disease in second half.

Publication: Pharma Marketletter
Publication Date: 31-MAR-03
Format: Online
Delivery: Immediate Online Access

Article Excerpt
The successful completion of two Phase III trials of Teva Pharmaceutical Industries and H Lundbeck's Parkinson's disease drug rasagiline mesylate have put the firms on track to file for approval in the second half of this year in both North America and Europe. Approval is anticipated in late 2004...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Dr Reddy's Allegra clone., March 31, 2003
Polish pharma sector revenues up 28.8%., March 31, 2003
Euro investors urge pharma over Rx access., March 31, 2003
Czech Republic pharma market data for 2002., March 31, 2003
Forthcoming conferences and meetings., March 31, 2003

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.